80
μ  6 ν EDISON SW ν™μ© κ²½μ§„λ€ν
72
Simulation of Pharmacokinetics and Receptor Occupancy of
Monoclonal Antibody Exhibiting Target-Mediated Drug
Disposition
λ°•μ™„μ, μ„λ™μ„ *
μ„μΈνΉλ³„μ‹ μ„μ΄κµ¬ λ°ν¬λ€λ΅ 222, κ°€ν†¨λ¦­λ€ν•™κµ μ•½λ¦¬ν•™κµμ‹¤
E-mail: wansu.park@catholic.ac.kr, yimds@catholic.ac.kr *
μ΄λ΅ λ³Έ μ—°κµ¬μ λ©μ μ€ λ‹¨ν΄λ΅ ν•­μ²΄ (mAb) μ•½λ™ν•™μ  νΉμ„±μ„ λ³΄λ‹¤ μ‰½κ² μ΄ν•΄ν•κ³ μ
λ¬Έν—μ— λ³΄κ³ λ mAbμ PK λ¨λΈμ„ κµ¬ν„ν•  μ μλ„λ΅ μ‹λ®¬λ μ΄μ… λ¨λΈμ„ λ§λ“λ”
κ²ƒμ΄λ‹¤. λ³Έ μ—°κµ¬κ²°κ³Όλ¥Ό λ°”νƒ•μΌλ΅ μ•½λ¬Όμ μ©λ²•/μ©λ‰, κ°κ°μ λ¨λΈ νλΌλ―Έν„°μ λ³€ν™”μ—
λ”°λ¥Έ νμ¤‘λ†λ„, μμ©μ²΄ μ μ—¬ λ“±μ λ³€ν™”λ¥Ό λ‹¤μ–‘ν•κ² μ‹λ®¬λ μ΄μ… ν•΄λ³Ό μ μλ‹¤.
μ„λ΅ 
λ‹¨ν΄λ΅ ν•­μ²΄ (monoclonal antibody; mAb) μ•½λ¬Ό
μ κ°λ°μ΄ λ§μ•„μ§€κ³  μμΌλ©° μ΄μ—λ”°λΌ mAb μ•½λ™
ν•™ (pharmacokinetics; PK)μ νΉμ§•μ„ μ νμ•…ν•λ”
κ²ƒμ€ μ‹ μ•½κ°λ° κ³Όμ • μ¤‘ PKμ μμΈ΅μ΄λ‚ μ©λ‰/μ©λ²•
μ„ μ •μ—μ„ μμ–΄ λ§¤μ° μ¤‘μ”ν•λ‹¤. λ§μ€ mAbλ“¤μ΄ μ•½
λ¬Όμ νƒ€κ²μ— μν•΄ μ•½λ¬Ό μ†μ‹¤μ— μν–¥μ„ λ°›λ” νƒ€κ²
-λ§¤κ° μ•½λ¬Όλ°°μΉ (target-mediated drug
dispostion; TMDD) ν„μƒμ„ λ³΄μ΄λ©° λ”°λΌμ„ TMDD
λ¨λΈμ„ μ΄μ©ν•μ—¬ mAbμ PK νΉμ„±μ„ μΆ€λ” μ •λ‰μ 
μΌλ΅ νμ•…ν•  μ μλ‹¤. λ¨λΈμ„ ν†µν•΄ μ•½λ¬Όμ νμ¤‘λ†
λ„μ™€ νƒ€κ²μ΄ μ–Όλ§λ‚ μ μ λμ–΄ μλ”μ§€ μμΈ΅μ΄ κ°€
λ¥ν•λ‹¤. μ΄ μ—°κµ¬μ λ©μ μ€ κΈ°μ΅΄μ— λ³΄κ³ λ λ¬Έν—μ
TMDD λ¨λΈ [1]μ„ μλ΅ μ΄μ©ν•μ—¬ mAbμ PK λ°
μμ©μ²΄ μ μ  (receptor occupancy; RO)λ¥Ό μ‹λ®¬λ 
μ΄μ…μ„ ν†µν•΄ μ¬ν„ν•΄ λ³΄λ” κ²ƒμ΄λ‹¤.
μ΄λ΅ 
TMDD λ¨λΈμ— λ€ν• μΆ€λ” μƒμ„Έν• λ‚΄μ©μ€ μ΄μ „
λ…Όλ¬Έμ— μμ„Έν μ†κ°λμ–΄ μλ‹¤. [2] μ΄ μ—°κµ¬μ—μ„ μ°Έ
κ³ λ΅ ν• μ•½λ¬Όμ λ¨λΈ κµ¬μ΅°λ” Figure 1
Figure 16. Strucutrure of TMDD Model
κ³Ό κ°™λ‹¤. μ΄ μ•½λ¬Όμ€ μƒν”Όμ„Έν¬μ„±μ¥μΈμ μμ©μ²΄
(Endothelial Growth Factor Receptor, EGFR)μ κΈΈ
ν•­μ λ΅ EGFRμ€ μ£Όλ΅ λ§μ΄μ΅°μ§μ— λ§μ΄ λ°ν„μ΄ λ
μ–΄ μκΈ° λ•λ¬Έμ— μ•½λ¬Όκ³Ό νƒ€κ²μ΄ μ£Όλ΅ λ§μ΄μ΅°μ§μ—
μ„ κ²°ν•©ν•λ” κ²ƒμ„ κ°€μ •μΌλ΅ ν• λ¨λΈμ΄λ‹¤. λ¨λΈ ν
λΌλ―Έν„°λ” free mAbμ clearance (CL A ), volume of
distribution (V c , V p ), intercompartment
clearance (Q), target synthesis rate (RB), target
clearance (CL B ), equilibrium binding constant
(K d ), complex clearance (CL C )λ“±μ΄ μλ‹¤.
Figure 1μ λ¨λΈμ λ―Έλ¶„λ°©μ •μ‹μ€ λ‹¤μκ³Ό κ°™λ‹¤.
π‘‘π‘‘π‘‘π‘‘
π‘‘π‘‘π‘‘π‘‘
= β’
π‘‘π‘‘β™π‘„π‘„
π‘‰π‘‰ π¶π¶
+
π‘‘π‘‘ π‘ƒπ‘ƒ β™π‘„π‘„
π‘‰π‘‰ π‘ƒπ‘ƒ
β’
π‘‘π‘‘β™π¶π¶π¶π¶ π΄π΄
π‘‰π‘‰ π¶π¶
(1)

73
π‘‘π‘‘π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ
π‘‘π‘‘π‘‘π‘‘
=
π‘‡π‘‡β™π‘„π‘„
π‘‰π‘‰ π¶π¶
β’
π‘‡π‘‡ π‘ƒπ‘ƒ β™π‘„π‘„
π‘‰π‘‰ π‘ƒπ‘ƒ
β’
π¶π¶β™π¶π¶π¶π¶ π¶π¶
π‘‰π‘‰ π‘ƒπ‘ƒ
(2)
π΄π΄ π‘ƒπ‘ƒ = π‘‡π‘‡π΄π΄ π‘ƒπ‘ƒ β’ π¶π¶ π‘ƒπ‘ƒ
(3)
π¶π¶ π‘ƒπ‘ƒ =
πΎπΎ π‘‘π‘‘ β™π‘‰π‘‰ π‘ƒπ‘ƒ +π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ +π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ β’ β(πΎπΎ π‘‘π‘‘ β™π‘‰π‘‰ π‘ƒπ‘ƒ +π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ +π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ ) 2 β’4β™π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ β™π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ
2
(4)
π‘‡π‘‡π‘‡π‘‡ π‘ƒπ‘ƒ =
π‘‰π‘‰ π‘ƒπ‘ƒ β™π‘…π‘…π‘‡π‘‡
π¶π¶π¶π¶ πµπµ
(5)
A λ” free antibody in central compartment, A p λ”
free antibody in peripheral compartment, C P λ”
target-antibody complex in the peripheral
compartment, TA P λ” total antibodies in the
peripheral compartment, TB P λ” total target
amount in peripheral compartmentλ¥Ό μλ―Έν•λ‹¤.
κ²°κ³Ό λ° λ…Όμ
μ΄ μ—°κµ¬μ—μ„λ” μ›μ­μ΄μ—μ„ μ–»μ€ PK νλΌλ―Έν„°μ™€
μ²΄μ¤‘μ μ°¨μ΄λ¥Ό κ³ λ ¤ν•μ—¬ μ‚¬λμ PK νλΌλ―Έν„°λ¥Ό
μμΈ΅ν• μ—°κµ¬μ΄λ©° μ‚¬λμ νλΌλ―Έν„°λ” μ‚¬λμ μ²΄μ¤‘
(70 kg)κ³Ό μ›μ­μ΄ μ²΄μ¤‘ (3 kg)μ„ κ³ λ ¤ν•μ—¬ μ•„λμ™€
κ°™μ€ μ‹μΌλ΅ κ³„μ‚°λμ—κ³  μ‹λ®¬λ μ΄μ…μ— μ‚¬μ©λ ν
λΌλ―Έν„°λ” Table 1μ— μ”μ•½λμ–΄ μλ‹¤.
π‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒ β„π‘Άπ‘Άπ‘Άπ‘Άπ‘Άπ‘Άπ‘Άπ‘Ά = π‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒπ‘ƒ π‘Άπ‘Άπ‘π‘π‘Άπ‘Άπ‘π‘π‘π‘π‘π‘ Γ—(70/3) π‘π‘π‘’π‘’π‘’π‘’π‘π‘π‘Άπ‘Άπ‘π‘π‘Άπ‘Άπ‘‘π‘‘
Parameters Exponent
GC1118
Monkey Human a
CL A (ml/h) 0.75 0.975 10.4
V C (ml) 1.0 141 3290
Q (ml/h) 0.75 3.87 41.1
V P (ml) 1.0 90.4 2109
RB (pmol/h) 0.85 284 4131
CL B (ml/h) 0.75 1.66 17.6
K d (nM) - 0.533 0.16 b
Table 8. TMDD parameters used for simulation
λ¨λΈμ„ μ΄μ©ν•μ—¬ μ‚¬λμ—κ² 400 mg/m 2 λ¥Ό 1μ‹
κ°„ λ™μ• μ •λ§¥μ£Όμ… ν•μ€μ„ λ• μ‹κ°„μ— λ”°λ¥Έ νμ¤‘λ†
λ„μ™€ μμ©μ²΄ μ μ λ¥Ό μ‹λ®¬λ μ΄μ… ν•΄λ³Έ κ²°κ³Όλ”
Figure 2μ™€ κ°™λ‹¤.
Figure 17. Simulated serum concentration (left)
and receptor occupancy (right) versus time
profiles of mAb following single intravenous
infusion
κ²°λ΅ 
TMDDλ¥Ό λ³΄μ΄λ” μ•½λ¬Όμ μ©λ‰, κ° νλΌλ―Έν„°μ
λ³€ν™”μ— λ”°λ¥Έ PKμ™€ ROμ λ³€ν™”λ¥Ό μ‹λ®¬λ μ΄μ… ν•΄λ΄„
μΌλ΅μ¨ TMDD λ¨λΈ λ° mAb PKμ νΉμ„±μ„ νμ•…ν•΄
λ³Ό μ μμ—λ‹¤.
κ°μ‚¬μ κΈ€
λ³Έ λ…Όλ¬Έμ€ 2016λ…„λ„ μ •λ¶€(λ―Έλμ°½μ΅°κ³Όν•™λ¶€)μ
μ¬μ›μΌλ΅ ν•κµ­μ—°κµ¬μ¬λ‹¨ μ²¨λ‹¨ μ‚¬μ΄μ–Έμ¤Β·κµμ΅ ν—λΈ
κ°λ° μ‚¬μ—…μ μ§€μ›μ„ λ°›μ•„ μν–‰λ μ—°κµ¬μ„(NRF-
2016-936606).
μ°Έκ³ λ¬Έν—
[1 ] WS Park, S. Han, J. Lee, T. Hong, J. Won, Y. Lim, et
al. Basic Clin. Pharmacol. Toxicol. 120:243 (2017)
[2] D. E. Mager and W. J. Jusko. J. Pharmacokinet.
Pharmacodyn. 28:507 (2001)

